Pfizer makes new case for controversial Mylotarg

Pfizer ($PFE) has potentially found a second life for its controversial blood cancer drug Mylotarg, Bloomberg reports. From 2000 to 2010, the drug was used to treat patients with acute myeloid leukemia--aged 60 or older--after their cancer had returned. But the FDA asked Pfizer to stop selling it last year after a post-marketing trial showed the drug wasn't helping patients and some died from related liver complications. A new study showed that Mylotarg, along with chemotherapy, helped prolong the lives of patients who were just diagnosed with the deadly cancer, compared with chemotherapy alone. Story